Search for: "Kirin v. Kirin" Results 1 - 20 of 83
Sort by Relevance | Sort by Date
RSS Subscribe: 20 results | 100 results
18 Dec 2023, 3:05 am by INFORRM
On 14 December 2023 there was a set aside application in the case of McGee v Lewis before Collins Rice J. [read post]
10 Jun 2023, 4:02 pm by Henry P Yang
 The third panel (photo: Neil Graveney)Trevor Cook (photo: Neil Graveney)Trevor Cook recalled that 20 years ago his team appealed to the House of Lords in Kirin-Amgen. [read post]
27 Mar 2023, 9:50 am by centerforartlaw
Head of R-Space Kirin Lee explained that luxury brands, streetwear, and virtual fashion would be central to the platform’s long-term NFT strategy.[4]Trendsetters shop for digital garments from R-Space, taking pictures of themselves wearing designer pieces that cannot be manufactured in the real world and sharing the pictures with fans. [read post]
24 Oct 2022, 1:00 am by Annsley Merelle Ward
On whether a particle is dish-shaped, the Judge indicated that both Kirin-Amgen [2004] UKHL 46 and Anan Kasei [2019] EWCA Civ 1646 distinguished a fuzzy boundary from conceptual uncertainty. [read post]
14 Nov 2019, 6:43 am
Guestkat Rose Hughes walked us through the court's reasoning in relation to the Biogen and Kirin-Amgen cases.GuestKat Rose Hughes responded to an anonymous Katfriend tipper and reported on an interesting update in the progress of the CRISPR/Broad Institute appeal (T0844/18). [read post]
1 Nov 2019, 6:02 am
 In Neo v Anan Kasei([2019]EWCA Civ 1646) the Court of Appeal again considered the thorny issue of insufficiency, both the Kirin-Amgenand the Biogen kind. [read post]
13 Aug 2019, 4:20 pm by Rik Lambers
Rik LambersWhile the numerous recent court decisions may suggest so, the ‘F’ in FRAND does not stand for ‘Fashionable’. [read post]
25 Jun 2019, 9:28 am
Little did the PatKat know, but she wasabout to get a message from the Dutchcourt saying that all may not be well in theland of equivalenceThe pemetrexed saga has, by now, obtained a hit-series-like status, with new decisions coming regularly and even more decisions yet to come. [read post]
24 Oct 2018, 3:49 am
In Actavis Lord Neuberger ruled that, contrary to Kirin-Amgen v Hoescht ([2004] UKHL 46) a court may rely on the prosecution history to determine the scope of a patent, if this would unambiguously resolve a point or if it would be contrary to the public interest for the contents of the file to be ignored (paragraph 88). [read post]
12 Jul 2018, 6:19 am by Brian Cordery
The Warner-Lambert v Actavis case concerning the drug pregabalin was heard by the Supreme Court in mid-February 2018 and considered, among other things, plausibility, infringement of second medical use patents and abuse of process. [read post]
29 Jun 2018, 3:08 am by Brian Cordery
Brian Corderyby Craig Lumb After a decade-long hiatus, so-called Arrow declarations are now firmly back in fashion after the Court of Appeal’s judgment last year in Fujifilm Kyowa Kirin Biologics Co, Ltd v Abbvie Biotechnology Ltd & Anor [2017] EWCA Civ 1. [read post]
6 Apr 2018, 3:42 am by Brian Cordery
The principles to be applied to such inventions have been summarised by the House of Lords in Kirin-Amgen and Lundbeck. [read post]
28 Mar 2018, 8:14 am
VEGF-Trap is therefore one of those improvements which Lord Hoffmann had in mind in Kirin-Amgen [2004] UKHL 46, [2005] RPC 9 at [117]. [read post]
3 Mar 2018, 4:02 am by Peter Groves
It's now 13 years since Lord Hoffmann told us definitively how to interpret patents claims, in his opinion in Kirin Amgen v Hoechst Marion Roussel [2005] 1 All ER 667. [read post]
29 Jan 2018, 2:57 am
Are the famous words of Lord Hoffman in Kirin-Amgen that "life is too short" to consider the file, soon to ring hollow? [read post]
19 Jan 2018, 3:58 am
Readers interested in patent law will be familiar with last summer's decision of the UK Supreme Court in Actavis v Eli Lilly [2017] UKSC 48. [read post]
24 Nov 2017, 7:07 am by Brian Cordery
Handed down by Henry Carr J on 21 November, Illumina v Premaitha considered aspects of Actavis and much more besides. [read post]
8 Nov 2017, 5:29 am
While noting the embarrassment and difficulty in commenting on your own cases, he explained that the difficulty with Kirin Amgen is that it is difficult to reconcile with the approach in Improver Corp v Remington Consumer Products Ltd [1990] FSR 181 - if it really all comes down to a matter of claim interpretation, then you don't need to go into the three Improver questions. [read post]